CompletedPhase 2NCT05142553

Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hipra Scientific, S.L.U
Principal Investigator
Teresa Prat
HIPRA SCIENTIFIC
Intervention
COVID-19 Vaccine HIPRA(biological)
Enrollment
887 target
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (10)

Collaborators

Laboratorios Hipra, S.A.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05142553 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials